



Biotech Daily

Monday November 16, 2009

Daily news on ASX-listed biotechnology companies

- * **ASX, BIOTECH UP: AVEXA UP 24%; CYTOPIA DOWN 10.5%**
- * **LIVING CELL 25¢ SHARE PLAN TO RAISE MORE THAN \$2m**
- * **FLUOROTECHNICS SAYS ITS GELS 20% BETTER THAN OTHERS**
- * **AVEXA PLEADS SCHULTZ TO ASX 21% QUERY; UP 100% IN 40 DAYS**
- * **STARPHARMA EXTENDS CAPITAL RAISING HALT TO SUSPENSION**
- * **NEUREN EXTENDS CAPITAL RAISING HALT TO SUSPENSION**
- * **KARMELSONIX SIGNS TWO INTERIM DISTRIBUTION AGREEMENTS**
- * **SOLAGRAN CHAIRMAN MISSES AGM TO MEET RUSSIAN PRESIDENT**

MARKET REPORT

The Australian stock market climbed 1.04 percent on Monday November 16, 2009 with the S&P ASX 200 up 48.8 points to 4,755.2.4 points.

Fifteen of the Biotech Daily Top 40 stocks were up, 10 fell, 10 traded unchanged and five were untraded.

Avexa was best, up 4.5 cents or 23.7 percent to 23.5 cents with 15.1 million shares traded, followed by Circadian up 6.4 percent to 74.5 cents on small volumes.

Alchemia climbed 5.8 percent; Cathrx, Nanosonics and Phylogica were up more than four percent; Cellestis, Mesoblast, Phosphagenics and Tissue Therapies were up more than three percent; Chemgenex and Genetic Technologies rose more than two percent; with Pharmaxis, Psivida, Resmed and Sirtex up more than one percent.

Cytopia led the falls, down one cent or 10.53 percent to 8.5 cents with 105,556 shares traded.

Benitec and Novogen lost more than six percent; Genera fell 4.44 percent; Universal Biosensors was down 3.2 percent; Biota and Sunshine Heart shed more than two percent; with Bionomics and Living Cell down more than one percent.

LIVING CELL TECHNOLOGIES

Living Cell is offering eligible shareholders parcels of shares from \$500 to \$15,000 each at 25 cents a share.

Living Cell said the record date was November 18, 2009, the share plan would open on November 19 and close on December 11, 2009.

The company said the funds raised would be used to finance the its operations for the clinical trials of its Diabecell, encapsulated porcine islets of Langerhans for type 1 diabetics.

Living Cell chief executive officer Dr Paul Tan told Biotech Daily that the share plan was in response to shareholders requests following the recent placement which raised \$4.2 million (BD: Jul 30, 2009).

Dr Tan said that from the requests he expected to raise "a few million dollars" and at least \$2 million.

Living Cell fell half a cent or 1.85 percent to 26.5 cents.

FLUOROTECHNICS

Fluorotechnics says a study it funded has shown its high performance electrophoresis (HPE) gels are superior to its competitors.

Fluorotechnics said its subsidiary the Gelcompany commissioned Germany's Greifswald University to compare its electrophoresis or the electrical dispersion of particles with existing systems.

The company said its HPE system of consumables and equipment enabled scientists to better measure biological processes using horizontal high performance electrophoresis.

The company said the trial by Greifswald's University Institute for Microbiology was conducted at "one of the world's leading proteomic research facilities".

Fluorotechnics said its HPE system delivered up to 20 percent more identified spots and due to the gel and buffer system, the spots were sharper and had higher protein concentration, in particular the low molecular weight proteins showed sharper spots.

The company said its gels provided "much improved reproducibility, which together with less labor resources required, leads to a much higher productivity of the 2-D process".

Tests were performed in the Institute's specialty area of bacterial infections with the study based on 120 gels for each approach, Fluorotechnics said.

The Institute's Knut Buettner said the results were "proof that Gelcompany's HPE system is the best electrophoresis system available anywhere to date".

Fluorotechnics chief executive officer James Walker said the results along with "the fact it is easier, faster and cleaner we have a major leap forward in proteomics research".

"We initially stated the system could detect 10 percent more proteins rather than the 20 percent figure Knut Buettner's research has shown," Mr Walker said.

Fluorotechnics said the HPE system used new technology enabling higher resolution, reproducibility and easier to use 1D and 2D gel electrophoresis separations than any other system.

The company said its system eliminated time-consuming vertical electrophoresis glass gel cassettes, instead using quality-controlled, pre-cast gels on plastic backing laid onto cooling plates.

Fluorotechnics said the HPE pre-cast gels came in standard 12.5cm x 25cm and large sized 20cm x 26cm with adjustable electrode positions for both sizes.

The company said non-fluorescent film backing was available for fluorescent detection, together with standard film backing for visible staining.

Fluorotechnics was unchanged at 35 cents.

AVEXA

Avexa has told the ASX that it was not aware of any information it had not announced which, if known, could explain recent trading in its securities.

The ASX said the company's share price rose from 19 cents on November 13, 2009 to 23 cents, a 21.05 percent increase, on November 16, 2009 with an increase in volumes.

Avexa was 11.5 cents as recently as October 6, 2009.

Avexa said its loss for the half year to December 31, 2009 was expected to be "at least 40 percent less than the loss for the previous corresponding period".

Avexa was up 4.5 cents or 23.7 percent to 23.5 cents with 15.1 million shares traded.

STARPHARMA

Starpharma has requested a suspension to follow on from the trading halt requested on November 12, 2009 relating to a proposed rights issue and placement.

Starpharma last traded at 60 cents.

NEUREN

Neuren has requested a suspension to follow on from the trading halt requested on November 12, 2009 relating to a proposed rights issue and placement.

Neuren last traded at 5.1 cents.

KARMELSONIX

Karmelsonix says MR Diagnostics SRO will be its exclusive distributors for the Czech Republic and Slovenia for its Pulmotrack respiratory diagnostic system.

Karmelsonix said Sanrosan SA would be its exclusive distributor for Spain.

The company said orders had been received from Sanrosan for the Pulmotrack system and Wheezometers and both contracts were interim.

Karmelsonix was unchanged at five cents.

SOLAGRAN

Solagran chairman Dr Vagif Soultanov and director Alexander Kurganov will be in Siberia meeting Russian Federation President Dmitri Medvedev at the time of the annual meeting. Solagran said Dr Soultanov had been "personally invited to meet with the President during his visit" to Tomsk on November 24 and 25, 2009.

Solagran said the Russian President's visit coincided with the launch of Ropren in Russia and Solagran's annual meeting, which would proceed as planned but with no formal presentations and no general question time.

"Shareholders attending should note that they will only have the opportunity to ask questions in relation to the business of the meeting," Solagran said.

The meeting will be held at the Lake Room, Sebel and Citigate Hotel, 65 Queens Road Melbourne on November 23, 2009 at 12pm. Dr Soultanov and Mr Kurganov will attend a shareholders' information session on December 9, 2009.

Solagran was up 2.5 cents or 13.2 percent to 21.5 cents.